When was Talus founded?

Talus was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Talus located?

Talus is headquartered in Seattle, United States.

Who is the current CEO of Talus?

Alex Federation of Talus. They have also founded 2 companies.

How many employees does Talus have?

As of Jul 01, 2024, the latest employee count at Talus is 10.

Is Talus a funded company?

Talus is a funded company, having raised a total of $19.8M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2020.

When was the latest funding round of Talus?

Talus' latest funding was a $***** Grant (prize money) round on Feb 21, 2025, with participation from 1 investor.

Where does Talus rank among its competitors?

Talus ranks 263rd amongst 3430 active competitors, of which 1173 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Talus, which secured $11.2M in Jul, 2024.

Who are the top competitors of Talus?

Talus' top competitors include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Among them, Talus secured the most recent funding round in February, 2025.

Talus - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of drug discovery platform for gene regulators. The company provides a functional proteomics platform MARMOT focused on studying full-length GRPs in an unmodified cellular environment. It allows the development of therapeutics against the disease-causing GRPs.

Website: www.talus.bio/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2020

Location

Seattle, United States

Stage

Seed

Total Funding

$19.8M in 7 rounds

Latest Funding Round

Grant (prize money), Feb 21, 2025, $*****

Investors

Y Combinator & 11 more

Ranked

263^rd among 3430 active competitors

Employee Count

10 as on Jul 01, 2024

Similar Companies

Jazz Pharmaceuticals & 3300 more

View Talus' full profile

Talus is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TALUS INC. CIN: 2169266 , United States, Active	Aug 12, 1988	-	-	-

Talus has raised a total funding of $19.8M over 7 rounds. Its first funding round was on 2020. Its latest funding round was a Grant (prize money) round on Feb 21, 2025 for $*****. 1 investor participated in its latest round. Talus has 12 institutional investors.

Here is the list of recent funding rounds of Talus:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 21, 2025	6029391	Grant (prize money)	4857731	6833831	6744140	6619047
Jul 29, 2024	8434087	Seed	1840655	4110136	5993150	Washington Research Foundation & 4 more
Aug 18, 2023	9675020	Grant (prize money)	5453487	1326829	9526807	Wacarefund & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Talus's funding rounds and investors

The founders of Talus are Alex Federation and Lindsay Pino. Alex Federation is the CEO of Talus.

Here are the details of Talus' key team members:

Alex Federation: Co-Founder & CEO of Talus and founder of 1 other company.
Lindsay Pino: Co-Founder of Talus.

View details of Talus's Founder profiles and Board Members

Talus' employee count trend

Talus has 10 employees as of Jul 24. Here is Talus's employee count trend over the years:

Uncover Talus' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Talus include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Talus, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Vivo Capital & 10 others	79/100
3rd	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Tamburi Investment Partners ... & 4 others	78/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Baillie Gifford & 17 others	75/100
5th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of drugs based on T-Cell receptor technology for the treatment of cancer	$601M	BlackRock, General Atlantic & 50 others	74/100
8th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Forbion & 20 others	72/100
9th	FibroGen 1993, San Francisco (United States), Public	Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology.	$215M	Adage Capital Management, Corriente Biotechnology Partners ... & 26 others	72/100
10th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
263rd	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	FCVC, Fifty Years & 10 others	59/100